Revelation Biosciences Inc expected to post a loss of $4.45 a share - Earnings Preview
RefinitivMeno di 1 minuto di lettura
Revelation Biosciences Inc
REVB is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Revelation Biosciences Inc is for a loss of $4.45 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Revelation Biosciences Inc is $512.18, about 99.5% above its last closing price of $2.54
Accedi o crea un account gratuito per leggere queste notizie